Tesamorelin 2026: Visceral Fat Trial Data, Egrifta WR Dosage, FDA Warning Letters & CJC-1295 Comparison

Tesamorelin is the only FDA-approved GHRH analog, and the 2026 peptide crackdown put it back in the headlines. Here's what the phase 3, liver-fat and cognition trials actually showed, how Egrifta WR is dosed, and how it compares with CJC-1295, sermorelin and GLP-1s.